Germany's federal cabinet postponed the decision to abolish the one-year tax-free holding period for crypto assets, keeping the current rule in place for 2026. A draft proposing to tax crypto gains as capital income with a flat 25% rate for assets acquired after December 31, 2026, remains under inter-ministerial review and has not been adopted. This means crypto holders can still sell assets held over a year tax-free in 2026, while new rules may apply from 2027 if approved. Investors should maintain detailed records of acquisition dates and prices due to potential changes and tax documentation requirements.
The crypto holding period reform status provides context for readers following cryptocurrency developments. For readers following crypto assets, here is Pluang's market snapshot as of Oct 17, 2026 01:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 19 rose and 30 fell today. Notable movers include CAKE (PancakeSwap) at Rp38.400 with a 1-day change of -4.00% and a typical hold time of 75 days, CRV (Curve DAO Token) at Rp6.181 with a 1-day change of -3.93% and a typical hold time of 62 days, and UNI (Uniswap) at Rp128.298 with a 1-day change of -3.32% and a typical hold time of 65 days.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
